CAPLYTA has proven efficacy in adults across bipolar I depression, bipolar II depression, and schizophrenia1

For bipolar I and II depression in adults

Proven antidepressant efficacy for bipolar I and bipolar II depression at 6 weeks as monotherapy and as adjunctive therapy with lithium or valproate1-3*

Primary efficacy measure: change from baseline in MADRS total score1-3

-16.7 mean change from
baseline with CAPLYTA vs.
-12.1 with placebo (P <0.0001)

-4.6 ptPlacebo-subtracted difference

Monotherapy

-16.9 mean change from
baseline with CAPLYTA vs.
-14.5 with placebo (P=0.0206)

-2.4 ptPlacebo-subtracted difference

Adjunctive (with lithium or valproate)

MADRS=Montgomery-Åsberg Depression Rating Scale.

*Monotherapy placebo-subtracted difference (95% CI): -4.6 (-6.3, -2.8); adjunctive therapy placebo-subtracted difference (95% CI): -2.4 (-4.4, -0.4).

Primary Efficacy & Study Design

Efficacy measured across a range of scales4

Significant improvement in disease and depression severity

See CAPLYTA results vs. placebo in the CGI‑BP‑S total and depression scores.

Disease Severity

Change in quality of life, enjoyment, and satisfaction

See results as measured by the Q-LES-Q-SF scale at 6 weeks.

Quality of Life Scale

Post hoc analysis

See results in bipolar II depression as measured by MADRS, and CGI‑BP‑S total and depression scores.

Bipolar II Pooled Data

For schizophrenia in adults

In 2 clinical trials, CAPLYTA demonstrated statistically superior improvement vs placebo at 4 weeks (P<0.05) in symptoms of schizophrenia1

Primary efficacy measure: change in PANSS total score vs placebo1

-13.2 mean change from baseline with CAPLYTA vs.
-7.4 with placebo (P<0.05)

5.8 ptReduction over placebo

Study 1

-14.5 mean change from baseline with CAPLYTA vs.
-10.3 with placebo (P<0.05)

4.2 ptReduction over placebo

Study 2

Primary Efficacy & Study Design

Efficacy evaluated across multiple measures5

Change in PANSS subscale scores

See how CAPLYTA performed vs. placebo.

PANSS Subscale

Change in prosocial symptoms

See how CAPLYTA performed vs. placebo.

Prosocial Subscale

Frequently Asked Questions

When was CAPLYTA approved?
CAPLYTA was approved for the treatment of schizophrenia in adults in December 2019 & for the treatment of bipolar I & bipolar II depression in December 2021.6,7
Where were CAPLYTA clinical trials conducted?
In schizophrenia, Phase 3 trials were conducted entirely in the United States. Bipolar depression studies were conducted in both the United States as well as international sites.8,9

CAPLYTA is indicated in adults for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder (bipolar depression), as monotherapy and as adjunctive therapy with lithium or valproate.

Important Safety Information

Boxed Warnings:

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.
  • Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. The safety and effectiveness of CAPLYTA have not been established in pediatric patients.

Contraindications: CAPLYTA is contraindicated in patients with known hypersensitivity to lumateperone or any components of CAPLYTA. Reactions have included pruritus, rash (e.g., allergic dermatitis, papular rash, and generalized rash), and urticaria.

Warnings & Precautions: Antipsychotic drugs have been reported to cause:

  • Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis, including stroke and transient ischemic attack. See Boxed Warning above.
  • Neuroleptic Malignant Syndrome, which is a potentially fatal reaction. Signs and symptoms include hyperpyrexia, muscle rigidity, delirium, autonomic instability, elevated creatinine phosphokinase, myoglobinuria (and/or rhabdomyolysis), and acute renal failure. Manage with immediate discontinuation of CAPLYTA and provide intensive symptomatic treatment and monitoring.
  • Tardive Dyskinesia (TD), a syndrome of potentially irreversible, dyskinetic, and involuntary movements which may increase as the duration of treatment and total cumulative dose increases. The syndrome can develop after a relatively brief treatment period, even at low doses, or after treatment discontinuation. Given these considerations, CAPLYTA should be prescribed in a manner most likely to reduce the risk of TD. Discontinue CAPLYTA if clinically appropriate.
  • Metabolic Changes, including hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain. Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma or death, has been reported in patients treated with antipsychotics. Measure weight and assess fasting plasma glucose and lipids when initiating CAPLYTA and monitor periodically during long-term treatment.
  • Leukopenia, Neutropenia, and Agranulocytosis (including fatal cases). Perform complete blood counts in patients with pre-existing low white blood cell count (WBC) or history of leukopenia or neutropenia. Discontinue CAPLYTA if clinically significant decline in WBC occurs in absence of other causative factors.
  • Orthostatic Hypotension and Syncope. Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease. Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension.
  • Falls. CAPLYTA may cause somnolence, postural hypotension, and motor and/or sensory instability, which may lead to falls and, consequently, fractures and other injuries. Assess patients for risk when using CAPLYTA.
  • Seizures. Use CAPLYTA cautiously in patients with a history of seizures or with conditions that lower seizure threshold.
  • Potential for Cognitive and Motor Impairment. Advise patients to use caution when operating machinery or motor vehicles until they know how CAPLYTA affects them.
  • Body Temperature Dysregulation. Use CAPLYTA with caution in patients who may experience conditions that may increase core body temperature such as strenuous exercise, extreme heat, dehydration, or concomitant anticholinergics.
  • Dysphagia. Use CAPLYTA with caution in patients at risk for aspiration.

Drug Interactions: Avoid concomitant use with CYP3A4 inducers. Reduce dose for concomitant use with strong CYP3A4 inhibitors (10.5 mg) or moderate CYP3A4 inhibitors (21 mg).

Special Populations: Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Reduce dose for patients with moderate or severe hepatic impairment (21 mg).

Adverse Reactions: The most common adverse reactions in clinical trials with CAPLYTA vs placebo were:

  • Schizophrenia: somnolence/sedation (24% vs 10%) and dry mouth (6% vs 2%).
  • Bipolar Depression (Monotherapy, Adjunctive therapy): somnolence/sedation (13% vs 3%, 13% vs 3%), dizziness (8% vs 4%, 11% vs 2%), nausea (8% vs 3%, 9% vs 4%), and dry mouth (5% vs 1%, 5% vs 1%).

CAPLYTA is available in 10.5 mg, 21 mg, and 42 mg capsules.

Indications

CAPLYTA is indicated in adults for the treatment of schizophrenia and depressive episodes associated with bipolar I or II disorder (bipolar depression), as monotherapy and as adjunctive therapy with lithium or valproate.

Please see full Prescribing Information, including Boxed Warnings.

References: 1. CAPLYTA prescribing information. 2. Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry. Published online September 23, 2021. Accessed May 1, 2024. doi:10.1176/appi.apj.2021.20091339. 3. Suppes T, Durgam S, Kozauer SG, et al. Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial [published online ahead of print, 2023 Feb 13]. Bipolar Disord. 2023;10.1111/bdi.13310. Accessed May 1, 2024. doi:10.1111/bdi.13310. 4. Data on File (REF-01374, REF-01376, REF-01468, REF-01761, REF-01763, REF-01764). 5. Lieberman JA, Davis RE, Correll CU, et al. CAPLYTA for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016;79(12):952-961. Accessed May 1, 2024. 6. Center for Drug Evaluation and Research. (n.d.). Novel drug approvals for 2019. U.S. Food and Drug Administration. Accessed May 1, 2024. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019. 7. Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults | Intra-Cellular Therapies Inc. ir.intracellulartherapies.com. https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-us-fda-approval-caplytar. 8. Research C for DE and Drug Trials Snapshots: CAPLYTA. FDA. Published online January 14, 2020. Accessed May 1, 2024. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-caplyta#:~:text=All%20trials%20were%20conducted%20in. 9. National Library of Medicine. Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally. Published online June 6, 2022. Accessed May 1, 2024. https://clinicaltrials.gov/study/NCT03249376.

Boxed Warnings:

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis.